Journal article

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Jeanne Tie, Joshua D Cohen, Yuxuan Wang, Michael Christie, Koen Simons, Margaret Lee, Rachel Wong, Suzanne Kosmider, Sumitra Ananda, Joseph McKendrick, Belinda Lee, Jin Hee Cho, Ian Faragher, Ian T Jones, Janine Ptak, Mary J Schaeffer, Natalie Silliman, Lisa Dobbyn, Lu Li, Cristian Tomasetti Show all

JAMA Oncology | AMER MEDICAL ASSOC | Published : 2019


Importance: Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be determined. Postsurgical circulating tumor DNA (ctDNA) analysis can detect minimal residual disease and is associated with recurrence in colorectal cancers. Objective: To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy efficacy in stage III colon cancer. Design, Setting, and Participants: This multicenter, Australian, population-based cohort biomarker study..

View full abstract


Awarded by Victorian Cancer Agency

Awarded by NIH

Funding Acknowledgements

This study was supported by Clinical Research Fellowship CRF14007 from the Victorian Cancer Agency (Dr Tie); grants P50-CA062924, CA06973, CA176828, and CA210170 from the NIH; the Virginia and D. K. Ludwig Fund for Cancer Research; and the John Templeton Foundation.